Chaque jour nous vous présenterons une nouvelle Startup française !
Notre pays regorge de talents et d'entrepreneurs brillants ! Alors partons à la découverte des meilleures startup françaises ! Certaines d'entre elles sont dans une étape essentielle dans la vie d'une startup : la recherche de financement, notamment par le financement participatif (ou crowdfunding en anglais). Alors participez à cette grande aventure en leur faisant une petite donation ! Les startups françaises ont besoin de vous !
So far, 2020 has been a year of turmoil and the global pandemic has added a new level of pressure to and reliance on the UK’s healthcare, life sciences and health technology sectors, writes Dona Ardeman, Partner with law firm Mills & Reeve.
In response to the pandemic, these sectors have had to mobilise and be innovative to formulate a vaccine, manufacture and re-design ventilators, develop technology to monitor any outbreak and protect the vulnerable in our society, all as part of our current fight against Coronavirus.
Life sciences and health tech funds are rising up to the challenge of innovation in healthcare and are supporting companies to introduce and implement revolutionary ideas to make our healthcare system, and those of other countries around the world, better equipped and stronger than before, to deal with future crises.
Cambridge-associated rising stars include funds recently set up by Start Codon, the o2h group and Future Care Capital. One key factor these funds share is they are ideally structured to support companies who can address issues arising from the pandemic.
Both Start Codon and the o2h group provide companies with high-tech facilities and work alongside its entrepreneurs to take their ideas and products to the next level.
Start Codon has recently set up an accelerator fund in Cambridge to invest in a range of healthcare and biotechnology-focused companies and provide early-stage companies with state-of-the-art labs, office space, mentoring as well as access to a dedicated team and network.
Start Codon’s innovative fund seeks to support companies with ideas that could positively impact the diagnosis, prevention or treatment of disease. It is a great example of a fund setting itself apart from the crowd and aiming to support its portfolio companies as they develop innovative businesses which will address some of the key problems the world is facing.
Also seeking to make a difference is o2h Ventures Limited’s Therapeutics Fund (also known as the o2h Human Health EIS Fund). Its target is to support and grow companies with new therapeutic drug opportunities or technologies.
The Therapeutics Fund nurtures companies with ideas to make significant impact in this space. They see this as a move away from the traditional fund investment landscape as, alongside its financial support, o2h Ventures Limited offers portfolio companies incubation in its Mill SciTech Park and support to carry out their first research experiments.
Finally, in collaboration with RYSE Asset Management LLP, Future Care Capital is launching a new fund, FCC RYSE Fund I LP, investing in companies in the healthcare industry who have the potential to significantly change the promotion or improvement of standards or training in the healthcare sector.
It is looking to invest in portfolio companies who are being innovative in the areas of digital health, assisted living, medical devices, education, training and development, with investments already envisaged in Cambridge.
Its prospective investments include Cambridge-based Healthera, a Cambridge-based company with a vision to build a single smart platform to digitise and provide medicines, healthcare services and other products for patients, pharmacies and GP practices.
These new life sciences and health teach funds will no doubt not only have a profound effect on Cambridge and continue to grow Cambridge’s biotech cluster, but may also have a wider positive impact on addressing problems arising from the pandemic.
With fund managers also engaging with entrepreneurs to overcome their hurdles and investing time to nurture life sciences businesses, we are bound to see new products supported by these funds coming to market.
• You can call Dona on +(44)(0)1223 222499 or drop her an email at: Dona.ardeman [at] mills-reeve.com
The global economic and societal challenges brought by COVID-19 have impacted all industries, many quite extensively, writes Simon Ormiston, partner at PwC in Cambridge.
In contrast, the performance of the life sciences sector has gone from strength to strength, with sentiment and confidence in it borne out by continuing significant scientific progress and levels of investment. This is exemplified by the Cambridge cluster, reinforcing its position as a leading centre globally and a key destination for businesses, research and investment.
A number of players here have made a huge contribution towards the COVID-19 testing, treatment and prevention efforts but it’s by no means all about the immediate challenges presented by COVID-19.
The IP developed in Cambridge addresses a broad spectrum of therapeutic targets and the strength and clinical potential of the drug candidates and platform technologies means there is significant investor appetite and activity – both from private and public sources.
If there were ever concerns that fund-raising would potentially dry up in the absence of face-to-face meetings whilst we have been working remotely, they were quickly dispelled. A number of substantial venture capital rounds were announced since March, which included:
Nodthera – $55 million Series B
ReViral Ltd – $44m Series C
Bit Bio – $41.5m Series A
Mission Therapeutics – $15m in equity investment
Biofidelity Ltd – $12m Series A
Despite initial concerns about the impact of COVID-19 on capital markets and IPO valuations, the IPO market has remained buoyant. NASDAQ seems to be by far and away the market of choice.
Bicycle Therapeutics listed there in May last year, and others, including Horizon Discovery and F-star Therapeutics (via its recently announced merger with Spring Bank Pharmaceuticals) have announced that they are evaluating such a move, and plenty of others are waiting in the wings.
Cambridge also continues to provide corporates with high potential and successful IP and products to strengthen their offerings, such as Nanna Therapeutics’ sale to Astellas Pharma Inc and NeoGenomics’ investment in, and option to buy, Inivata.
The focus on industry corridors is of increasing importance to economic development and spatial development strategies. Down the A1 corridor from Cambridge is the Stevenage bioscience catalyst and its growing cluster of leading edge life sciences companies are also contributing to the strength of the UK life sciences industry.
This includes the recent $120m series C investment into Freeline Therapeutics and their announcement of an IPO, and Bayer’s acquisition of KaNDy Therapeutics.
The links between the two centres are becoming stronger, which should help with the continued acceleration and performance of the wider cluster, building the deeper and larger talent pool so necessary for future expansion of the industry.
In these ongoing uncertain economic times, it is more important than ever that the life science cluster here in Cambridge celebrates and builds on its successes!
For more information, email simon.j.ormiston [at] pwc.com (Simon Ormiston).
Illumina’s $8bn holy GRAIL as it launches new era of cancer detection
Genomic sequencing supernova Illumina, whose European research HQ is in Cambridge UK, is paying $8 billion in cash and stock to acquire California healthcare business GRAIL and spark… Read full article online
Frontier Developments named Business of the Year
Frontier Developments, Cambridge’s world-leading video games developer is today unveiled as Business of the Year in the toughest competition in 30 years of the Business Weekly Awards… Read full article online
Magnifique as CMR Surgical robots wow French market
Surgical robotics innovation from a Cambridge-based world leader has penetrated one of the world’s biggest markets for the technology.
Facebook and Be the Business provide free digital training for local businesses
Be the Business, a not-for-profit movement bidding to help every firm in the country improve their performance, is partnering with Facebook to host an event in the East of England… Read full article online
Government seeks new Innovate UK lead as Campbell joins LifeArc
The UK Government is looking to recruit a new Executive Chair for Innovate UK. The position had been held on an interim basis by Dr Ian Campbell after former Pfizer Neusentis CSO… Read full article online
UKRI invests millions in trials using whole genome sequencing to beat cancer
UK Research and Innovation (UKRI) has injected £8 million into seven clinical trials which are using whole genome sequencing to defeat cancer.
Genomic sequencing supernova Illumina, whose European research HQ is in Cambridge UK, is paying $8 billion in cash and stock to acquire California healthcare business GRAIL and spark a new era of cancer detection technology.
The move looks a master stroke as the play addresses a market forecast to grow to $75bn by 2035.
GRAIL stockholders will also receive future payments representing a tiered single digit percentage of certain GRAIL-related revenues. The deal has been backed by both companies’ boards.
Francis deSouza, Illumina’s president and chief executive officer, has no doubts the move is a game-changer in the fight against cancer.
He said: “Over the last four years GRAIL’s talented team has made exceptional progress in developing the technology and clinical data required to launch the GalleriTM multi-cancer screening test.
“Galleri is among the most promising new tools in the fight against cancer, and we are thrilled to welcome GRAIL back to Illumina to help transform cancer care using genomics and our NGS platform.
“Together we have an important opportunity to introduce routine and broadly available blood-based screening that enables early cancer detection when treatment can be more effective and less costly.
“Multi-cancer early detection is better for patients, their physicians, and payors. As we accelerate our path to clinical leadership and the path to multi-cancer early detection, we will continue to drive significant value creation for our stockholders.”
The deal is very much a case of ‘back to the future’ for Illumina. GRAIL was founded by Illumina in 2016 and spun out as a standalone company, powered by Illumina’s NGS technology, to develop state-of-the-art data science and machine learning and create the atlas of cancer signals in the blood, enabling multi-cancer early detection tests.
GRAIL raised around $2 billion to support its innovative technology platform and develop Galleri. An earlier version of Galleri was able to detect more than 50 cancer types, over 45 of which have no recommended screening in the United States.
Nextgen Galleri is expected to launch commercially in 2021 as a multi-cancer, laboratory developed test for early cancer detection from blood. GRAIL plans to follow Galleri with future blood-based tests for cancer diagnosis, detection and post-treatment monitoring of cancer patients.
CEO Hans Bishop said: “Cancer is one of society’s most significant challenges with most cancer being detected too late. We believe multi-cancer early detection technology could address a tremendous unmet need and reduce the cancer burden worldwide.
“Combining forces with Illumina enables broader and faster adoption of GRAIL’s innovative, multi-cancer early detection blood test, enhancing patient access and expanding global reach.
“We are excited about this next step in our journey to transform cancer detection and outcomes and create value for patients and their families and communities, health care providers and payors, employers, and stockholders.”
The cash consideration to GRAIL stockholders excluding Illumina of approximately $3.1bn is expected to be funded using balance sheet cash of both Illumina and GRAIL plus up to $1bn in capital raised through either a debt or equity issuance.
In advance of this anticipated issuance, Illumina has obtained financing commitments for a $1bn bridge facility with Goldman Sachs Bank USA.
Frontier Developments, Cambridge’s world-leading video games developer is today unveiled as Business of the Year in the toughest competition in 30 years of the Business Weekly Awards.
The company, which passed a billion dollar valuation in the summer, held off a strong challenge from surgical robotics pioneer CMR Surgical to take the honours.
Although the honours were based on the last 12 months of trading, 2020 is going even better for Frontier. At the start of this week the share price soared 125p to 2,550 (up 5.15 per cent) and the market cap tipped $1.26 billion.
While only privately held startups qualify as unicorns, Frontier’s achievements set against the impact of COVID-19 on capital markets is little short of sensational. And, as we said in an exclusive article recently, there is much more to come: The industry is already valued at $150 billion and is forecast to grow at a conservative 10 per cent a year.
Frontier has gone from strength to strength since transitioning to a new business model and listing on the AIM market in 2013 and 2020 marks a golden age for the enterprise despite coronavirus.
The company has a number of highly anticipated partnerships on the table that are being rolled out imminently and over the coming years; its strong track record over many years as both a developer and a publisher has seen its share price grow more than ten-fold in less than four years.
Frontier’s ‘launch and nurture’ strategy for its immersive games including Elite Dangerous, Planet Coaster, Jurassic World Evolution and Planet Zoo, is holding the business in high esteem within the gaming community.
Its recently established foothold in the third-party publishing business also has investors excited. With five development partners signed in less than 12 months, this publishing business looks set to add further value to Frontier’s already prosperous portfolio.
Cambridge unicorn business CMR Surgical won the inaugural Sir Michael Marshall Engineering Excellence Award for the innovation and development inherent in its Versius robot arm for keyhole surgeons.
In late July we reported that the company had engineered a potentially lucrative new market in the Gulf for its Versius robotic arm for keyhole surgery. CMR experienced a strong start to 2020 with new installations and orders in markets including the UK, India, Italy and France.
As part of its accelerating global rollout, CMR formed a partnership with Gulf Drug – a medical equipment supplier in the United Arab Emirates – to take Versius to this strategically important region, increasing its commercial presence across Asia and the Middle East.
Strong progress has been made as part of the Versius clinical programme, with over 600 clinical cases successfully completed across gynaecology, upper GI, urology and colorectal surgery.
CMR Surgical joined the ranks of Cambridge’s $billion valued unicorns with a £195m Series C raise and has recently further strengthened its senior management team as it continues to grow worldwide.
Redgate Software, shrewdly led by CEO and co-founder Simon Galbraith, wins the International Trade Champion Award. The company is a soaraway success on the global stage, selling database development solutions.
It produced a stroke of genius in terms of global growth last year when it decided to invest $10 million in the acquisition and ongoing development of the biggest cross-platform database migrations tool, Flyway.
Already widely known for its SQL Server expertise, the move was a ‘killer’ play – designed to accelerate Redgate’s plans to enable the database to be included in DevOps, whatever database technology its customers are working on.
The Disruptive Technology Award goes to GeoSpock, the Cambridge extreme data technology pioneer. As we have previously and exclusively revealed, the company is in the process of wrapping up a megabucks and transformational investment round to underpin further international expansion.
GeoSpock has some exciting strategic investors lined up that are well positioned to ensure the company represents the de facto database powering telco IoT and Smart City deployments globally. We are further assured that the company has some major lines of business ‘cooking’ in Asia where appetite for GeoSpock’s technology continues to grow.
Tech Scale-Up of the Year winner, UltraSoC was acquired for multimillions this summer by Texas-headquartered Siemens Digital Industries Software.
UltraSoC provides instrumentation and analytics solutions that put intelligent monitoring, cybersecurity and functional safety capabilities into the core hardware of system-on-chip.
Prior to the Siemens acquisition, UltraSoc had closed a £5 million equity funding round, opened an engineering centre in Warsaw, recruited substantially in Cambridge and Bristol and increased its commercial presence in Europe, the US, Japan and China.
Biotech Scale-Up of the Year Evonetix is developing a desktop platform for scalable, high-fidelity and rapid gene synthesis. It is collaborating with US company Analog Devices Inc to fast-track the development and scale-up of the UK innovator’s desktop DNA writer. The technology will help facilitate the rapidly growing multibillion-dollar synthetic biology industry, Evonetix says.
Evonetix’ novel silicon chip controls the synthesis of DNA at many thousands of independently controlled reaction sites or ‘pixels’ on the chip surface in a highly parallel fashion.
Cambridge cell technology gamechanger Mogrify celebrates a double success in the Business Weekly Awards. The young company won the fiercely contested Life Science Innovation Award, sponsored by global Big Biotech AstraZeneca while co-founder and chief scientific officer Julian Gough is named Cambridge Enterprise Academic Entrepreneur of the Year.
Spearheaded by entrepreneur and CEO Dr Darrin Disley, Mogrify® has developed a proprietary direct cellular conversion technology which makes it possible to enhance existing stem-cell forward reprogramming methods or bypass development pathways altogether, effecting a direct transdifferentiation between a mature cell type to another mature cell type.
Leveraging advanced datasets of next-generation sequencing and regulatory networks, Mogrify is deploying this platform to engineer an evergreen and scalable source of cell types that exhibit efficacy and safety profiles necessary to transform the development of ex vivo cell therapies or in vivo reprogramming therapies for diseases with a high unmet clinical need.
After a stellar performance in its first year of operation which saw the company raise $20 million of start-up capital, $2.5m grant funding and close several deals with US BioPharma, Mogrify pivoted its business model to become a developer of ex vivo cell therapies as well as in vivo reprogramming therapies for indications of unmet need in haematology, immunology and ophthalmology.
The company is progressing these programs through pre-clinical development whilst forming strategic alliances with major European, US and Japanese biopharma players.
Healx is our AI Innovation winner. Only last October, Healx – which is leveraging AI technology to repurpose drugs to treat the planet’s rarest diseases – raised $56 million in a Series B round backed by Japanese and European investors to take its haul in a calendar year to around $66m.
In the last three months the company has agreed further significant global collaborations in uncharted areas of rare disease. Healx is looking to double its headcount by the start of 2021.
Young Company of the Year is Wellcome Sanger Institute spin-out Microbiotica; at just over three years old Microbiotica is the startup equivalent of an infant prodigy. And its potential for growth from young legs is immense.
The company recently joined forces with Cancer Research UK and Cambridge University Hospitals NHS Foundation Trust to pilot a major new cancer initiative.
Microbiotica was launched in December 2016 with the aim of creating a global leader to exploit the leading microbiome science built at Sanger. The new collaboration is designed to identify and develop microbiome co-therapeutics and biomarkers for cancer patients receiving immune checkpoint inhibitor therapy.
PROWLER.io, which is leading the UK’s push to become the AI technology capital of the world, won the Cambridge Judge Business School Graduate Business of the Year accolade. Among its founders and its growing workforce abounds Cambridge academic talent.
PROWLER.io was founded by mathematicians and engineers following years of research into machine intelligence, probability theory and multi-agent problems. Founded in 2016, it now has more than 110 employees from 29 countries.
Cambridge Judge Business School Woman Entrepreneur of the Year is Martina King, the CEO of Cambridge’s world-leading machine learning company Featurespace. The company’s international growth under King’s inspired leadership, with a technology based on University of Cambridge IP, made her the outstanding candidate for the Award this year.
King has also helped take the company into a thriving enterprise in the United States where headcount and contracts are rocketing.
Cambridge Enterprise, the university’s commercialisation arm, was thrilled to select Mogrify CSO and co-founder Julian Gough as winner of its Academic Entrepreneur of the Year Award.
Mogrify CEO Dr Darrin Disley said the honour was thoroughly deserved: “Julian Gough is a very well deserved winner of the Academic Entrepreneur of the Year accolade. His drive and perseverance in the period 2016 to 2019 is the sole reason Mogrify was able to bridge the transition from a tripartite academic collaboration into an emerging biotech of sufficient calibre to attract Ahren Innovation Capital to invest, myself to take over the helm as CEO and for pharma industry leaders such as Dr Jane Osbourn and Dr Lorenz Mayer to join the board of directors.”
Dr Hermann Hauser won the Cambridge Enterprise Lifetime Achievement Award: Co-founder of the iconic Acorn Computers; co-founder of Arm, the world’s greatest superchip innovator; co-founder of Amadeus Capital Partners – Dr Hauser would figure centre stage in pretty much any global academic and corporate company. Dr Hauser expressed himself “flattered” to be chosen.
Cambridge Enterprise CEO Dr Tony Raven felt Dr Hauser was long overdue recognition for putting the cluster on the world business map and working hard to keep it there.
This is the third year that this particular accolade has been awarded. Nobel Prizewinner Sir Greg Winter was the inaugural champion and last year the prize was shared by the co-founders of genomics sequencing trailblazer Solexa, Sir Shankar Balasubramanian and Sir David Klenerman. All the winners to date are knights of the Realm or British Empire.
The UK/China Award sponsored by Cambridge China Centre was won by TusPark, which has pioneered a beautiful biotechnology innovation hub at the Science Park and also invested in a number of local businesses. “It’s such an honour that TusPark UK has been awarded the The UK/China Award,” a spokesperson said.
TusPark UK is a magnificent ambassador for two-way trade between the territories and its flagship Bio-Innovation Centre at Cambridge Science Park is already making big headlines through the quality of its initial tenant companies.
Superchip architect Arm, which has agreed a $40 billion takeover by US company NVIDIA, wins the Kate Gross Prize for Social Enterprise. Last year, President and chief operating officer Graham Budd took an Arm team to tcheat with a battery of smart technologies to combat medical, food, flooding and other life-threatening crises.
It is one of many such global initiatives where Arm staff and management are adapting bleeding edge wearable and other technology to the needs of people in deprived areas of the globe.
The Business Weekly Awards were due to be presented at a gala dinner in March but the lockdown guillotined those plans. Attempts have been ongoing to hold a physical presentation around now but the Government’s new rule of six has again intervened – unless we meet in plus fours pretending we are shooting grouse or stage an impromptu fox hunt. The fox has been donated by – no, forget it.
Instead, lead forensic sponsor Mills & Reeve – the Cambridge based global law firm – will host a staggered presentation event within the next few weeks at which a representative of each winning company will receive their Award from one of the sponsors on a socially distanced and staged basis.
We will be launching the 2020-2021 Awards next week and are already taking entries. All the major sponsors have renewed their backing for the next Awards competition – a huge show of faith in the merit of the competition and their stated regard for Business Weekly’s role in promoting Cambridge on a world stage.
THE 30th Anniversary Business Weekly Award winners at a glance:
Business of the Year – Frontier Developments
Michael Marshall Engineering Excellence – CMR Surgical
International Trade Champion – Redgate Software
Young Company of the Year – Microbiotica
Disruptive Technology – Geospock
Life Science Innovation Mogrify
AI Innovation – Healx
Biotech Scale-up of the Year – Evonetix
Tech Scale-up of the Year – UltraSoC
The UK/China Award – TusPark UK
Kate Gross Prize for Social Enterprise – Arm
Cambridge Enterprise Lifetime Achievement Award – Dr Hermann Hauser
Cambridge Judge Business School Woman Entrepreneur of the Year –
Martina King (Featurespace)
Cambridge Enterprise Academic Entrepreneur of the Year – Julian Gough (Mogrify)
Cambridge Judge Business School Graduate Business of the Year – PROWLER.io
The Covid-19 pandemic divided the country into two camps, and I don’t mean the healthy and the vulnerable, but the selfish and the selfless. In the latter category is a near neighbour of mine, who has popped a note through every letterbox in our street offering to run errands for the ill and elderly.
In the other category were the bog roll bandits and needlessly greedy scourers of the supermarket shelves.
The equivalent, in our business, are the corporately responsible and irresponsible. In the latter category are those who played on people’s fears by offering medical supplies – face masks are a favourite – for which they make extravagant claims (they will prevent or cure viral infection) and for which they charge inflated prices. Fortunately, the ASA clamped down on the worst of these ‘spivs’.
On the other hand, are those who committed funds to support Corvid-19 response ($15 million – approximately £7 million – in the case of Nike), as well as embracing the same spirit in their advertising.
Nike’s Covid campaign made the statement: “If you ever dreamed of playing for millions around the world, now’s your chance. Play inside, play for the world”. It strikes a nice balance, doesn’t it, between appealing to its customers sporting ambitions and their humanity, their consideration for others.
Nike are experts at building brand loyalty whilst creating individual product/range appeal. Massive budgets aside, their ideas and the execution of those ideas is spot on. And it’s always the ideas that count.
Their advertising sometimes falls between brand advertising and public service advertising. Similar examples might be the breweries urging pub goers to ‘Drink responsibly’ and turf accountants advising punters: ‘When the fun stops, stop’. However, a responsible five second message dissuading you from doing something tacked on to the end of a twenty five second message persuading you to do it, has limited value in my book.
As far as real public service advertising is concerned, perhaps Boris should go the whole hog and it’s time to revive some of those old WW2 classics – ‘Dig for Victory’ (the way food prices are going we’ll soon all need to grow our own!), ‘Make Do and Mend’ (ditto for clothing and consumer goods), and if you want to strike a Churchillian note (and we know he does), ‘Let Us Go Forward Together’.
However, I honestly feel that for business in general and marketing in particular ‘Keep Calm and Carry On’ might be the best message for now.
US tech giant NVIDIA piled on the sugar and honey with jam on the side as it reeled off the positives of its $40 billion acquisition of Cambridge silicon superhero Arm. Rather than swallowing hype about the deal hitting the sweet spot, critics triggered an alert for wasps and a potentially deadly sting.
Arm’s Japanese parent SoftBank has agreed terms for the deal and emphasised an upside that looks fabulous for Cambridge and the UK on the face of it:-
A new and world-leading Artificial Intelligence megahub for Cambridge
A $1.5bn equity windfall for Arm employees, potentially triggering a fresh wave of tech startups funded by newly created Arm millionaires
A pledge to keep the superchip architect’s HQ in Cambridge and not move it to California
Promises to grow headcount rather than cut jobs here and to physically grow Arm’s Cambridge mothership.
The decision to exclude Arm’s potentially world-beating IoT Services Group from the acquisition.
Too good to be true? Cambridge entrepreneur Hermann Hauser thinks so and has been backed by scores of executives in an open letter to Boris Johnson warning the PM to intervene.
The UK government has promised to inspect the terms of the deal; the proposed transaction is subject to customary closing conditions, including the receipt of regulatory approvals for the UK, China, the EU and the US.
Completion of the transaction is expected to take place in approximately 18 months. That leaves room for a riptide of water to flow under a number of global bridges. Independent observers are pointing out that this could either prove the greatest thing that has ever happened to Cambridge technology or turn into a bloodbath at a time when the UK government is struggling to strike trade deals with world powers.
NVIDIA says it will create the world’s greatest AI research superhub in the UK’s leading technology cluster. It will be based at Arm’s existing Cambridge HQ building, which has been significantly extended in the last couple of years.
The Artificial Intelligence nervecentre will embrace a startup accelerator, international research collaborations, training and Fellowships. It will host an Arm-based supercomputer; the facility will serve as a broad-based hub for collaboration by AI researchers, scientists and startups across the UK and internationally.
NVIDIA says: “We are excited to be creating a world-class AI laboratory in Cambridge at the Arm headquarters: a Hadron collider or Hubble telescope, if you like, for artificial intelligence.
“NVIDIA is the leader in AI computing while Arm is present across a vast ecosystem of edge devices, with more than 180 billion units shipped. With this newly announced combination, we are creating the leading computing company for the age of AI.”
Arm CEO Simon Segars was upbeat about the proposed deal, saying: “Arm and NVIDIA share a vision and passion that ubiquitous, energy-efficient computing will help address the world’s most pressing issues from climate change to healthcare, from agriculture to education.”
“Delivering on this vision requires new approaches to hardware and software and a long-term commitment to research and development. By bringing together the technical strengths of our two companies we can accelerate our progress and create new solutions that will enable a global ecosystem of innovators. My management team and I are excited to be joining NVIDIA so we can write this next chapter together.”
Arm co-founder Hermann Hauser, representing a global cohort of complainants, doesn’t agree. He tells the PM: “We are concerned about the impact on jobs in Cambridge, Manchester, Belfast, Glasgow, Sheffield and Warwick where thousands of Arm employees work.
“The sale of Arm to Nvidia will destroy the very basis of Arm’s business model which is to be the Switzerland of the semiconductor industry dealing in an even-handed way with its over 500 licensees. Most of them are Nvidia’s competitors. Among them are many UK companies. Assurances to the contrary should be legally binding.
“Most importantly for the long term, it is an issue of national economic sovereignty: Arm is the only remaining UK technology company with a dominant position in mobile phone microprocessors. It has a market share of over 95 per cent.
“The UK has suffered from American technology dominance by companies like Google, Facebook, Amazon, Netflix, Apple and others. As the American president has weaponised technology dominance in his trade war with China, the UK will become collateral damage unless it has its own trade weapons to bargain with.
“Arm powers the smartphones of Apple, Samsung, Sony, Huawei and practically every other brand in the world and therefore can exert influence on all of them.
“A sale to Nvidia will mean that Arm becomes subject to the US OFAC regulations. There are hundreds of companies in the UK electronics industry employing tens of thousands of people who use Arm in their products. Many of them export to major global markets including China. They will all have to comply with the US OFAC regulations.
“This puts Britain in the invidious position that the decision about who Arm is allowed to sell to will be made in the White House and not in Downing Street. Surrendering UK’s most powerful trade weapon to the US is making Britain a US vassal state.”
Dr Hauser demands legally binding job guarantees for all Arm employees in the UK and a legally binding agreement that NVIDIA must not gain any preferential treatment over other Arm licensees.
He says the natural alternative to an Arm sale to NVIDIA is to take Arm public on the London Stock Exchange and make it a British owned company again with a Golden Share for national economic security.
And he lays it on the line to Boris Johnson: “As you have spent £500m to help OneWeb out of Chapter 11, which arguably is not as important to Britain as Arm, you could spend £1-2bn as the anchor investor for an IPO on the London Stock Exchange and get a Golden Share for it so that this problem cannot happen again.
“If you do not make Arm a British owned company again with a Golden Share for national economic security, history will remember you as the person who, when the chips are down, failed to act in the national interest.”
Disrupting Japan is six years old and ready to party!
Unfortunately, we can’t. Like so much else in 2020, this year’s big, live show has been canceled, but I hope you’ll make it next year.
It’s not all bad news, of course. There are a lot of great things happening for both Disrupting Japan and for Japanese startups. So looking back on these six years, I’d like to share some of the most important changes that are happening in Japan.
Leave a comment
Welcome to Disrupting Japan, straight talk from Japan’s most successful entrepreneurs. I’m Tim Romero and thanks for joining me.
This is our sixth-anniversary episode. Over the past six years, it’s been a Disrupting Japan tradition to have our big Disrupting Japan Live and Unleashed show on our anniversary. We get three of Japan’s startup thought-leaders on stage and invite a few hundred of our closest friends over for an evening of drinks, conversation, and just hanging out with a lot of cool people.
Unfortunately, this year the coronavirus makes this impossible. So we’ll pick up that tradition again next year. What I had planned for this year’s anniversary episode was to tell you a special story about innovation at it’s best in Japan. The real story behind a video you’ve seen a dozen times on the internet and Western news media.
But before that, I wanted to talk briefly about three critical things that have changed for startups in Japan and as those introductory notes became longer and more interesting, I realized I was going to have to split the show, so I’ll tell you all about that video in a future episode.
Today, there is something else you should know.
But before we get to that, I want to thank you. When I started Disrupting Japan six years ago, I really could not have imagined what it would become. At first, Disrupting Japan was just me sitting down and talking with my founder friends, and I guess in all the important ways, it still is just me sitting down with my friends.
But Disrupting Japan has grown with Japan’s startup community. We now have around 10,000 listeners all over the world, and we’ve ranked as Japan’s #1 entrepreneurship podcast and occasionally break into the top five Japanese business podcasts as well.
So after six years, I want to thank all the amazing founders who have come on the show to tell us their stories so honestly, the fans who have spread the word about the podcast in a way that online marketing never could, and to thank you, for listening. I appreciate you choosing to spend your time with me, and I work incredibly hard to make sure this show is worth your time.
Looking back on six years, I want to share with you the three most important ways that Disrupting Japan has changed, and what that tells us about how things are changing for Japanese startups.
Now, these aren’t the big data-driven headline numbers that you already know about. These trends are more personal, more human, and maybe in a way, more important.
1) Origin Stories
During the first two years of Disrupting Japan, I would almost always ask founders about how they started their startup. Many had pretty dramatic stories. Many telling of how their wife or parents were opposed and tried to talk them out of it or force them out of it, or how they had to give up their apartment to save money meet payroll.
Many founders had a family role model. A non-conformist relative who was maybe an entrepreneur themselves, or perhaps an artist or musician. Someone who believed in them when everyone else doubted.
One of our founders even sold his wife’s jewelry to make payroll. Although his parting advice to me on that matter was “Tim, your startup is very important, but there are some things you should just never do.”
But as long-time listeners have probably noticed, we don’t hear those kinds of origin stories anymore. When I bother to ask the question these days, the most common reply is something like “Well, I really wanted to do it,
from Disrupting Japan: Startups and Innovation in Japan https://ift.tt/2FAVaI8